240 related articles for article (PubMed ID: 26138905)
1. Transient myeloproliferative disorder with partial trisomy 21.
Takahashi T; Inoue A; Yoshimoto J; Kanamitsu K; Taki T; Imada M; Yamada M; Ninomiya S; Toki T; Terui K; Ito E; Shimada A
Pediatr Blood Cancer; 2015 Nov; 62(11):2021-4. PubMed ID: 26138905
[TBL] [Abstract][Full Text] [Related]
2. Early lineage priming by trisomy of Erg leads to myeloproliferation in a Down syndrome model.
Ng AP; Hu Y; Metcalf D; Hyland CD; Ierino H; Phipson B; Wu D; Baldwin TM; Kauppi M; Kiu H; Di Rago L; Hilton DJ; Smyth GK; Alexander WS
PLoS Genet; 2015 May; 11(5):e1005211. PubMed ID: 25973911
[TBL] [Abstract][Full Text] [Related]
3. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
Malinge S; Bliss-Moreau M; Kirsammer G; Diebold L; Chlon T; Gurbuxani S; Crispino JD
J Clin Invest; 2012 Mar; 122(3):948-62. PubMed ID: 22354171
[TBL] [Abstract][Full Text] [Related]
4. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.
Alford KA; Reinhardt K; Garnett C; Norton A; Böhmer K; von Neuhoff C; Kolenova A; Marchi E; Klusmann JH; Roberts I; Hasle H; Reinhardt D; Vyas P;
Blood; 2011 Aug; 118(8):2222-38. PubMed ID: 21715302
[TBL] [Abstract][Full Text] [Related]
5. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
[TBL] [Abstract][Full Text] [Related]
6. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
[TBL] [Abstract][Full Text] [Related]
7. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
8. Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome.
Tsai MH; Hou JW; Yang CP; Yang PH; Chu SM; Hsu JF; Chiang MC; Huang HR
Indian J Pediatr; 2011 Jul; 78(7):826-32. PubMed ID: 21287369
[TBL] [Abstract][Full Text] [Related]
9. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
[TBL] [Abstract][Full Text] [Related]
10. Analysis of GATA1 mutations and leukemogenesis in newborns with Down syndrome.
Queiroz LB; Lima BD; Mazzeu JF; Camargo R; Córdoba MS; Q Magalhães I; Martins-de-Sá C; Ferrari I
Genet Mol Res; 2013 Oct; 12(4):4630-8. PubMed ID: 24222239
[TBL] [Abstract][Full Text] [Related]
11. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
[TBL] [Abstract][Full Text] [Related]
12. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
Roy A; Roberts I; Norton A; Vyas P
Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
[TBL] [Abstract][Full Text] [Related]
13. A neonate with a unique non-Down syndrome transient proliferative megakaryoblastic disease.
Bertrums EJ; Buijs A; van Grotel M; Dors N; de Rooij JD; de Haas V; Hopman S; Jongmans MC; Zwaan CM; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27667142
[TBL] [Abstract][Full Text] [Related]
14. [GATA1 analysis in myeloproliferative disorders associated to trisomy 21].
Fuster Soler JL; Norton A; Galera Miñarro A; Bermúdez Cortés M; Llinares Riestra ME; Ortuño Giner F
An Pediatr (Barc); 2011 Jan; 74(1):31-7. PubMed ID: 20870473
[TBL] [Abstract][Full Text] [Related]
15. Congenital GATA1-mutated myeloproliferative disorder in trisomy 21 complicated by placental fetal thrombotic vasculopathy.
Loh TJ; Lian DW; Iyer P; Lam JC; Kuick CH; Aung AC; Chang KT
Hum Pathol; 2014 Nov; 45(11):2364-7. PubMed ID: 25248574
[TBL] [Abstract][Full Text] [Related]
16. Generation of 2 isogenic clones from a patient with Trisomy 21 and a GATA1 mutation.
Takasaki K; Kumar SS; Gagne A; French DL; Chou ST
Stem Cell Res; 2023 Jun; 69():103098. PubMed ID: 37084616
[TBL] [Abstract][Full Text] [Related]
17. Systematic Cellular Disease Models Reveal Synergistic Interaction of Trisomy 21 and GATA1 Mutations in Hematopoietic Abnormalities.
Banno K; Omori S; Hirata K; Nawa N; Nakagawa N; Nishimura K; Ohtaka M; Nakanishi M; Sakuma T; Yamamoto T; Toki T; Ito E; Yamamoto T; Kokubu C; Takeda J; Taniguchi H; Arahori H; Wada K; Kitabatake Y; Ozono K
Cell Rep; 2016 May; 15(6):1228-41. PubMed ID: 27134169
[TBL] [Abstract][Full Text] [Related]
18. Evidence against the current hypothesis of "gene dosage effects" of trisomy 21: ets-2, encoded on chromosome 21" is not overexpressed in hearts of patients with Down Syndrome.
Greber-Platzer S; Schatzmann-Turhani D; Wollenek G; Lubec G
Biochem Biophys Res Commun; 1999 Jan; 254(2):395-9. PubMed ID: 9918849
[TBL] [Abstract][Full Text] [Related]
19. Transient myeloproliferative disorder with trisomy 12.
Basu B; Gupta V
Pediatr Hematol Oncol; 2010 Apr; 27(3):233-6. PubMed ID: 20367267
[TBL] [Abstract][Full Text] [Related]
20. The proto-oncogene ERG in megakaryoblastic leukemias.
Rainis L; Toki T; Pimanda JE; Rosenthal E; Machol K; Strehl S; Göttgens B; Ito E; Izraeli S
Cancer Res; 2005 Sep; 65(17):7596-602. PubMed ID: 16140924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]